Book Value per Share: zailaboratory.com (ZLAB)

Graphic logo of Zai Lab Limited (ZLAB)

This price visualization for Zai Lab Limited (ZLAB), which assists in the basic asset valuation, demonstrates the dynamics of a company whose revenue is based on the exclusive right to sell Western oncology drugs in Asia, ensuring stable payments. The current indicator stands at 5.37, although it is impacted by challenges with government reimbursement and political tensions between Washington and Beijing. Ultimate success depends on local trials and the stability of procurement in the PRC.

Zai Lab Ltd (ZLAB): Share Book Value from 07/04/2022 to 10/26/2026

zailaboratory.com - analytical breakdowns and key metrics (ZLAB)

- price and consensus price forecast:
Stock Price Zai Lab Ltd.|ZLAB - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Zai Lab Limited|ZLAB - Total Company Value
- book capitalization data:
Net Assets per Single Share Zai Lab|ZLAB - Net Asset Value|Market Capitalization to Book Value Ratio zailaboratory.com|ZLAB - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Zai Lab Limited|ZLAB - Long-Term Debt to Capital|Short-Term Debt to Equity Zai Lab|ZLAB - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Zai Lab Limited
Fundamental company valuation:Zai Lab Ltd. - ZLAB
Manufactured products of Zai Lab

Zai Lab Limited (ZLAB) commercializes Western innovations in China by leveraging patent protection and regulatory expertise. The book value per share reflects the company's residual capital minus all liabilities, measuring the actual tangible value of an investor's stake. Growth in this metric confirms the effective transformation of revenue into net assets. By analyzing the trajectory of the book value per share, one can assess business resilience. Stable price action here confirms the reliability of the licensing model.

Competitors of Zai Lab Limited (ZLAB)

Eli Lilly & Co. - Book Value per Share|ABBV - Book Value per Share|AstraZeneca PLC (AZN) - Book Value per Share|NVS (novartis.com) - Net Assets per Single Share|Net Assets per Single Share Merck MRK|Share Book Value Novo Nordisk AS|Amgen Corporation (AMGN) - Book Value per Share|Accounting Value of a Share Pfizer Corp (PFE)|Book Value per Share SNY (Sanofi)|bms.com - Book Value per Share|Net Assets per Single Share GSK Corp (GSK)|TAK: Accounting Value of a Share|TEVA (Teva) - Net Assets per Single Share|Dr. Reddy's Labs (RDY) - Accounting Value per Share|VTRS (Viatris Inc.) - Book Value per Share|Book Value per Share roivant.com (ROIV)|Bausch Health (BHC) - Accounting Value per Share|Accounting Value of a Share Cosmos Health, Inc. (COSM)